Skip to main content

The Delhi High Court granted an ex parte interim injunction restraining the defendants from marketing VARDENAFIL and VARDENAFIL HYDROCHLORIDE in India.

The court noted that the defendants product contained the plaintiff Bayer’s patented pharmaceutical preparation, but without its permission to exploit the same. The defendants’ drugs, though not commercially launched in India, were being exported to other countries.

Bayer initiated legal proceedings in India upon learning that drugs infringing its patent, valid till 2018, had been seized by customs authorities in Latvia.

Bayer Intellectual Property GmbH v Vipro Lifescience and anr.

Most Recent

News & Insights

VIEW ALL
Thought Leadership
Feb 13, 2026

‘First published on Enterprise IT World’ By: Subroto Kumar Panda How the 2026 IT Rule Amendments Protect You in the Age of AI In an era where seeing

The Digital Armor – 2026
Thought Leadership
Feb 11, 2026

Authors: Safir Anand, Mudit Kaushik and Sehr Anand The establishment of a new National Institute of Design (NID-East) in India’s eastern region,

Can New NID-East Ignite India’s Design Revolution?
News & Updates, Thought Leadership
Feb 10, 2026

‘First published on India Business Law Journal’ By: Dr. Ajai Garg and Subroto Kumar Panda Business has always been about risk, the balance between

Agentic AI: Productivity gains, risks and data demands today
News & Updates, Thought Leadership
Jan 30, 2026

First published by Lexology. Authors: Safir Anand and Omesh Puri In today’s innovation‑driven economy, design rights have become a core element of

Proposed Reforms to India’s Design Protection Framework